{"id":"cbaef2a0-755d-4162-b513-a1e4b53099be","dataset":"sourcesCorporatePublication","time":26,"normalizedUIQL":null,"lastDatasetUpdate":"2019-02-16T00:12:36Z","PagedResults":{"total":81,"firstRow":1,"lastRow":81,"Result":[{"Field":[{"name":"sourceId","type":"string","value":"1386159"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin SEDICO"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SEDICO Co"}],"pos":1},{"Field":[{"name":"sourceId","type":"string","value":"1080209"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin Analogs"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"New England Healthcare Institute"}],"pos":2},{"Field":[{"name":"sourceId","type":"string","value":"1073331"},{"name":"corporatePublicationTitle","type":"string","value":"Biodel: Pipeline, BIOD- Smart Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":3},{"Field":[{"name":"sourceId","type":"string","value":"606214"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk insulin product overview"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-06-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":4},{"Field":[{"name":"sourceId","type":"string","value":"765924"},{"name":"corporatePublicationTitle","type":"string","value":"Delivery of Biologics - oral insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-02-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MediVas LLC"}],"pos":5},{"Field":[{"name":"sourceId","type":"string","value":"1355810"},{"name":"corporatePublicationTitle","type":"string","value":"Ansulin - Insulin Human (rDNA) USP"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-01-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Square Pharmaceuticals Ltd"}],"pos":6},{"Field":[{"name":"sourceId","type":"string","value":"492583"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk US - Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":7},{"Field":[{"name":"sourceId","type":"string","value":"400110"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin glargine"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-02-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Aventis SA"}],"pos":8},{"Field":[{"name":"sourceId","type":"string","value":"372335"},{"name":"corporatePublicationTitle","type":"string","value":"Drug Development Pipeline - AERx (insulin)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":9},{"Field":[{"name":"sourceId","type":"string","value":"1489984"},{"name":"corporatePublicationTitle","type":"string","value":"Commissioning Support Insulin Degludec (Tresiba)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Keele University (Midlands Therapeutics Review & Advisory Committee)"}],"pos":10},{"Field":[{"name":"sourceId","type":"string","value":"662549"},{"name":"corporatePublicationTitle","type":"string","value":"Final Appraisal Determination - Long-acting insulin analogues for the treatment of diabetes – insulin glargine"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE"}],"pos":11},{"Field":[{"name":"sourceId","type":"string","value":"371716"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: phosphorylated human insulin, Diabecore"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Diabecore Medical Inc"}],"pos":12},{"Field":[{"name":"sourceId","type":"string","value":"2057870"},{"name":"corporatePublicationTitle","type":"string","value":"Drug Approval Document of SOLIQUA (insulin glargine / lixisenatide)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-07-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Health Surveillance Agency"}],"pos":13},{"Field":[{"name":"sourceId","type":"string","value":"1878395"},{"name":"corporatePublicationTitle","type":"string","value":"Over the counter covered product list (insulin)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MedicareBlue Rx"}],"pos":14},{"Field":[{"name":"sourceId","type":"string","value":"1215327"},{"name":"corporatePublicationTitle","type":"string","value":"AFREZZA - A Novel Ultra Rapid-Acting Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-08-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Mannkind Corp"}],"pos":15},{"Field":[{"name":"sourceId","type":"string","value":"988483"},{"name":"corporatePublicationTitle","type":"string","value":"Recombinant Human Pro-insulin C Peptide For Injection"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Newsummit Biopharma Co Ltd"}],"pos":16},{"Field":[{"name":"sourceId","type":"string","value":"1489875"},{"name":"corporatePublicationTitle","type":"string","value":"Review Afrezza Inhaled Insulin for Diabetes Mellitus"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-06-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Canadian Agency for Drugs and Technologies in Health"}],"pos":17},{"Field":[{"name":"sourceId","type":"string","value":"2061439"},{"name":"corporatePublicationTitle","type":"string","value":"Drug Approval Document of XULTOPHY (liraglutide; insulin degludec)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Health Surveillance Agency"}],"pos":18},{"Field":[{"name":"sourceId","type":"string","value":"1490319"},{"name":"corporatePublicationTitle","type":"string","value":"Evidence Summary - ESNM24: Type 1 diabetes: insulin degludec"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-10-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institute for Health and Care Excellence"}],"pos":19},{"Field":[{"name":"sourceId","type":"string","value":"1080451"},{"name":"corporatePublicationTitle","type":"string","value":"Drug datasheet: Humalog Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection)"},{"name":"corporatePublicationType","type":"string","value":"Drug Package Insert"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":20},{"Field":[{"name":"sourceId","type":"string","value":"1487298"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting - Briefing Document for Insulin Degludec and Insulin Degludec/Aspart"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-11-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":21},{"Field":[{"name":"sourceId","type":"string","value":"1726535"},{"name":"corporatePublicationTitle","type":"string","value":"Development of Novel Nanoemulsion for Insulin Oral Administration"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Innopharmax Inc"}],"pos":22},{"Field":[{"name":"sourceId","type":"string","value":"1713297"},{"name":"corporatePublicationTitle","type":"string","value":"Summary Basis of Decision for Basaglar (insulin glargine)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-10-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Health Canada"}],"pos":23},{"Field":[{"name":"sourceId","type":"string","value":"337500"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin (oral), Protein Delivery Inc"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-08-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Protein Delivery Inc"}],"pos":24},{"Field":[{"name":"sourceId","type":"string","value":"452854"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin (oral), Nobex/GlaxoSmithKline"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"GlaxoSmithKline plc"}],"pos":25},{"Field":[{"name":"sourceId","type":"string","value":"1765422"},{"name":"corporatePublicationTitle","type":"string","value":"UK launch for new insulin glargine biosimilar Abasaglar"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-09-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Diabetes.co.uk"}],"pos":26},{"Field":[{"name":"sourceId","type":"string","value":"1892390"},{"name":"corporatePublicationTitle","type":"string","value":"European public assessment report for Lusduna (insulin glargine)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-01-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"European Medicines Agency"}],"pos":27},{"Field":[{"name":"sourceId","type":"string","value":"903616"},{"name":"corporatePublicationTitle","type":"string","value":"Product information: Emisphere's oral insulin program"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-04-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Emisphere Technologies Inc"}],"pos":28},{"Field":[{"name":"sourceId","type":"string","value":"1075323"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk is discontinuing several insulin delivery devices"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":29},{"Field":[{"name":"sourceId","type":"string","value":"1211351"},{"name":"corporatePublicationTitle","type":"string","value":"Material safety data sheet : Insulin, Human"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":30},{"Field":[{"name":"sourceId","type":"string","value":"1490320"},{"name":"corporatePublicationTitle","type":"string","value":"Evidence Summary - ESNM25: Type 2 diabetes: insulin degludec"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-10-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institute for Health and Care Excellence"}],"pos":31},{"Field":[{"name":"sourceId","type":"string","value":"1080253"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin initiation in type 2 diabetes"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":32},{"Field":[{"name":"sourceId","type":"string","value":"1060682"},{"name":"corporatePublicationTitle","type":"string","value":"Early Communication About Safety of Lantus (insulin glargine)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-07-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"FDA"}],"pos":33},{"Field":[{"name":"sourceId","type":"string","value":"1994271"},{"name":"corporatePublicationTitle","type":"string","value":"Registration of NCEs: RYZODEG 70/30 FLEXTOUCH and RYZODEG 70/30 PENFILL (70% insulin degludec / 30% insulin aspart)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-11-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Therapeutic Goods Administration"}],"pos":34},{"Field":[{"name":"sourceId","type":"string","value":"1075229"},{"name":"corporatePublicationTitle","type":"string","value":"UPDATE: Discontinuation of Humulin 50/50 (50% Human Insulin Isophane Suspension and 50% Human Insulin Injection [rDNA Origin])"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":35},{"Field":[{"name":"sourceId","type":"string","value":"1491250"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk Briefing Document - FDA Endocrinologic and Metabolic Drug Advisory Committee - Insulin Degludec and Insulin Degludec/Insulin Aspart Treatment to Improve Glycemic Control in Patients with Diabetes Mellitus (NDAs 203314 and 203313)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-11-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":36},{"Field":[{"name":"sourceId","type":"string","value":"1544390"},{"name":"corporatePublicationTitle","type":"string","value":"Better Acceptance of a Single injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting (BASAAL PLUS)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-05-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"sanofi"}],"pos":37},{"Field":[{"name":"sourceId","type":"string","value":"1514128"},{"name":"corporatePublicationTitle","type":"string","value":"Efficacy and safety of intensive insulin therapy with insulin glulisine in patients with type 2 diabetes inadequately controlled with basal insulin and oral glucose-lowering drugs (CHANGING)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-06-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sanofi Aventis"}],"pos":38},{"Field":[{"name":"sourceId","type":"string","value":"1514957"},{"name":"corporatePublicationTitle","type":"string","value":"Treating Diabetes Using Menin Inhibitors to Regenerate Insulin Producing Beta Cells"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-02-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novapeutics LLc"}],"pos":39},{"Field":[{"name":"sourceId","type":"string","value":"220172"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Aztec, heprain (oral), Verex, insulin (oral), Verex"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-09-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Verex Laboratories Inc"}],"pos":40},{"Field":[{"name":"sourceId","type":"string","value":"1462312"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin Resistance - A Root Cause of Excess Weight, Obesity and Other Disorders"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-08-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Insulite Laboratories"}],"pos":41},{"Field":[{"name":"sourceId","type":"string","value":"407391"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin like growth factor receptor inhibitors"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-04-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Amgen Inc"}],"pos":42},{"Field":[{"name":"sourceId","type":"string","value":"602297"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: BN-006, oral GCSF, oral insulin, Diabetology"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-05-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Diabetology Ltd"}],"pos":43},{"Field":[{"name":"sourceId","type":"string","value":"1290723"},{"name":"corporatePublicationTitle","type":"string","value":"APC1 : a novel mechanism for treatment of diabetes type 2 Insulin Replacement Therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-05-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"TwoToBiotech Ltd"}],"pos":44},{"Field":[{"name":"sourceId","type":"string","value":"1386153"},{"name":"corporatePublicationTitle","type":"string","value":"Bioequivalance study of Insulin H Mix 100 IU Suspension"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SEDICO Co"}],"pos":45},{"Field":[{"name":"sourceId","type":"string","value":"1308834"},{"name":"corporatePublicationTitle","type":"string","value":"Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orgenesis Inc"}],"pos":46},{"Field":[{"name":"sourceId","type":"string","value":"2042984"},{"name":"corporatePublicationTitle","type":"string","value":"Registration of new generic medicines and biosimilar medicines: SEMGLEEE (insulin glargine)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2018-03-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Therapeutic Goods Administration"}],"pos":47},{"Field":[{"name":"sourceId","type":"string","value":"681826"},{"name":"corporatePublicationTitle","type":"string","value":"Pharmacodynamic Properties of VIAject: A Novel Rapid-Acting Regular Human Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-11-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":48},{"Field":[{"name":"sourceId","type":"string","value":"1387155"},{"name":"corporatePublicationTitle","type":"string","value":"The announcement of withdrew the clinical trial applications of insulin products"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Dongbao Group"}],"pos":49},{"Field":[{"name":"sourceId","type":"string","value":"1994265"},{"name":"corporatePublicationTitle","type":"string","value":"Registration of NCEs: TRESIBA FLEXTOUCH and TRESIBA PENFILL (insulin degludec)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-11-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Therapeutic Goods Administration"}],"pos":50},{"Field":[{"name":"sourceId","type":"string","value":"1519225"},{"name":"corporatePublicationTitle","type":"string","value":"1R43DK100186-01: HEXALOG: A RAPID-ACTING ULTRA-CONCENTRATED INSULIN FORMULATION"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-01-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Thermalin Diabetes LLC"}],"pos":51},{"Field":[{"name":"sourceId","type":"string","value":"1896517"},{"name":"corporatePublicationTitle","type":"string","value":"Australian Public Assessment Report for insulin glargine (Edomlus / Lambeto /Toujeo)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-01-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Therapeutic Goods Administration"}],"pos":52},{"Field":[{"name":"sourceId","type":"string","value":"1308836"},{"name":"corporatePublicationTitle","type":"string","value":"Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-06-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orgenesis Inc"}],"pos":53},{"Field":[{"name":"sourceId","type":"string","value":"1465365"},{"name":"corporatePublicationTitle","type":"string","value":"Product Pipeline - Afrezza - A Novel Ultra Rapid-Acting Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-08-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MannKind Corp"}],"pos":54},{"Field":[{"name":"sourceId","type":"string","value":"681825"},{"name":"corporatePublicationTitle","type":"string","value":"Pharmacodynamics of VIAject: A Novel Rapid Acting Regular Human Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-06-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":55},{"Field":[{"name":"sourceId","type":"string","value":"2117833"},{"name":"corporatePublicationTitle","type":"string","value":"Increlex (mecasermin); Recombinant Human Insulin-Like Growth Factor-1"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2018-11-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":56},{"Field":[{"name":"sourceId","type":"string","value":"805671"},{"name":"corporatePublicationTitle","type":"string","value":"A Randomised, Double-Blind, Placebo-Controlled Trial of Intranasal Insulin (40IU and 440IU) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II (INIT II)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-01-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Royal Melbourne Hospital"}],"pos":57},{"Field":[{"name":"sourceId","type":"string","value":"1917008"},{"name":"corporatePublicationTitle","type":"string","value":"The announcement about holding subsidiary's withdrawl of launch application for insulin lispro injection and its API"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-02-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Shanghai Fosun Pharmaceutical (Group) Co Ltd"}],"pos":58},{"Field":[{"name":"sourceId","type":"string","value":"1550383"},{"name":"corporatePublicationTitle","type":"string","value":"The tolerability and efficacy of oral insulin in Type 2 diabetes patients: A pilotclinical study"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-04-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Oramed Pharmaceuticals Inc"}],"pos":59},{"Field":[{"name":"sourceId","type":"string","value":"1697527"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: mecasermin, recombinant human insulin-like growth factor-1; Treatment of Rett Syndrome"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-09-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":60},{"Field":[{"name":"sourceId","type":"string","value":"1513868"},{"name":"corporatePublicationTitle","type":"string","value":"Multicenter, open, non-randomised controlled phase IV clinical trial of efficacy and safety for insulin glulisine injected subcutaneously in patients with type 1 diabetes mellitus using also insulin glargine"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":61},{"Field":[{"name":"sourceId","type":"string","value":"295420"},{"name":"corporatePublicationTitle","type":"string","value":"Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Planning phase IIa European trial in 3rd quarter"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-08-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PROVALIS Limited"}],"pos":62},{"Field":[{"name":"sourceId","type":"string","value":"312999"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Insulin Sensizer, TPO agonists, EPO agonist, Growth Hormone Modulator, Leptin Modulator, Interleukin Modulators, by Receptron"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-01-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Receptron Inc"}],"pos":63},{"Field":[{"name":"sourceId","type":"string","value":"1487841"},{"name":"corporatePublicationTitle","type":"string","value":"National Horizon Scanning - Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-12-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Health Service"}],"pos":64},{"Field":[{"name":"sourceId","type":"string","value":"231901"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: CADDYS (growth hormone), Emisphere/Lilly, oral insulin, Emisphere, cromolyn, Emisphere, parathyroid hormone, Emisphere"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-01-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Emisphere Technologies Inc"}],"pos":65},{"Field":[{"name":"sourceId","type":"string","value":"1649664"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: human insulin (rDNA); Treatment of short bowel syndrome (SBS)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-04-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":66},{"Field":[{"name":"sourceId","type":"string","value":"1080450"},{"name":"corporatePublicationTitle","type":"string","value":"Drug datasheet: Humalog (insulin lispro injection, USP (rDNA origin) 100 units per ml (U-100))"},{"name":"corporatePublicationType","type":"string","value":"Drug Package Insert"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":67},{"Field":[{"name":"sourceId","type":"string","value":"2057063"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein; Treatment of Mucopolysaccharidosis Type IIIA, Sanfilippo A Syndrome"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2018-07-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":68},{"Field":[{"name":"sourceId","type":"string","value":"662540"},{"name":"corporatePublicationTitle","type":"string","value":"National Institute for Health and Clinical Excellence: Inhaled insulin for the treatment of diabetes (types 1 and 2) - Appraisal consultation document"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-04-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institute for Health and Clinical Excellence"}],"pos":69},{"Field":[{"name":"sourceId","type":"string","value":"1134041"},{"name":"corporatePublicationTitle","type":"string","value":"Pharmacokinetics of novel formulations of insulin analogs providing a more rapid onset of action in the diabetic swine model"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-09-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":70},{"Field":[{"name":"sourceId","type":"string","value":"1389168"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Application; Results for Orphan Drug Product Designations Search: recombinant human Naglu- insulin-like growth factor II; Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-03-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":71},{"Field":[{"name":"sourceId","type":"string","value":"1488399"},{"name":"corporatePublicationTitle","type":"string","value":"HTA Report - Short-acting Insulin Analogues for Diabetes Mellitus: Meta-analysis of Clinical Outcomes and Assessment of Cost-effectiveness"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Canadian Agency for Drugs and Technologies in Health (CADTH)"}],"pos":72},{"Field":[{"name":"sourceId","type":"string","value":"1485180"},{"name":"corporatePublicationTitle","type":"string","value":"NN304-1938: A Multicenter, Open-label, Non-randomized, Non-interventional, Safety study in Patients With Type 2 Diabetes Treated With Insulin Detemir (Levemir)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-10-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":73},{"Field":[{"name":"sourceId","type":"string","value":"989576"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical Trial Report: A Multinational, Randomized, Controlled, Open-labeled, Parallel Group Evaluation in Terms of Efficacy and Safety of Metformin 1700 mg/day Plus Twice Daily Biphasic Insulin Aspart 30 or Human NPH-insulin in Subjects with Type 2 Diabetes"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-10-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":74},{"Field":[{"name":"sourceId","type":"string","value":"583719"},{"name":"corporatePublicationTitle","type":"string","value":"An open label, single arm study to investigate the tolerance, pharmacokinetics and efficacy of a repeated dose of basulin - a new long-acting insulin - in 30 type 1 diabetic patients"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-02-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Flamel Technologies SA"}],"pos":75},{"Field":[{"name":"sourceId","type":"string","value":"357450"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: sucralfate, APCls, insulin analogs, NPC-16377, NPC-16570, NPC-18166, adipsin, heparin-EGF-like factor, cell adhesion inhibitors, bradykinin antagonists, KPI-022, BY-2001"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-02-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Scios Inc"}],"pos":76},{"Field":[{"name":"sourceId","type":"string","value":"1383932"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Application;  Results for Orphan Drug Product Designations Search: human insulin beta chain peptide with incomplete Freund's adjuvant vaccine; Treatment of Type 1 diabetes patients with residual beta cell function"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":77},{"Field":[{"name":"sourceId","type":"string","value":"1544426"},{"name":"corporatePublicationTitle","type":"string","value":"A randomized, open-label study of the effect of PEGASYS ® plus COPEGUS® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naive patients with chronic hepatitis C, genotype-1, and insulin resistance"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":78},{"Field":[{"name":"sourceId","type":"string","value":"2072992"},{"name":"corporatePublicationTitle","type":"string","value":"Approved determinations and designations for prescription medicines: Orphan drug designation for mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2018-07-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Therapeutic Goods Administration"}],"pos":79},{"Field":[{"name":"sourceId","type":"string","value":"1609367"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: human trtravalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3); Treatment of pancreatic cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-10-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":80},{"Field":[{"name":"sourceId","type":"string","value":"1971015"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide sequence complementary to insulin-like growth factor type 1 receptor (IGF-1R) codons 2-7 in the IG-1R gene; Treatment of malignant glioma"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-10-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":81}]},"DatasetCounts":[],"HitTerms":{"Term":[{"value":"insulin"}],"Synonym":[]},"serviceExecutionTime":31}